Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2026 According to Harbour BioMed media release, first patient has been dosed.
09 Jun 2026 According to Sichuan Kelun-Biotech Biopharmaceutical media release, company announced that the first patients have been dosed in the Phase 2 SIRIUS study of WIN378, the companys ultra long-acting anti-TSLP monoclonal antibody, in patients with chronic obstructive pulmonary disease (COPD).
04 May 2026 According to Windward Bio media release, the trial is anticipated to start in the second quarter of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com